Skip to main content
Top
Published in: Journal of Neurology 10/2012

01-10-2012 | Original Communication

Comparison of clinical characteristics between familial and non-familial early onset Alzheimer’s disease

Authors: Simantini J. Karve, John M. Ringman, Albert S. Lee, Kevin O. Juarez, Mario F. Mendez

Published in: Journal of Neurology | Issue 10/2012

Login to get access

Abstract

Although familial Alzheimer’s disease (FAD) is an early onset AD (EAD), most patients with EAD do not have a familial disorder. Recent guidelines recommend testing for genes causing FAD only in those EAD patients with two first-degree relatives. However, some patients with FAD may lack a known family history or other indications for suspecting FAD but might nonetheless be carriers of FAD mutations. The study was aimed to identify clinical features that distinguish FAD from non-familial EAD (NF-EAD). A retrospective review of a university-based cohort of 32 FAD patients with PSEN1-related AD and 81 with NF-EAD was conducted. The PSEN1 patients, compared to the NF-EAD patients, had an earlier age of disease onset (41.8 ± 5.2 vs. 55.9 ± 4.8 years) and, at initial assessment, a longer disease duration (5.1 ± 3.4 vs. 3.3 ± 2.6 years) and lower MMSE scores (10.74 ± 8.0 vs. 20.95 ± 5.8). Patients with NF-EAD were more likely to present with non-memory deficits, particularly visuospatial symptoms, than were FAD patients. When age, disease duration, and MMSE scores were controlled in a logistical regression model, FAD patients were more likely to have significant headaches, myoclonus, gait abnormality, and pseudobulbar affect than those with NF-EAD. In addition to a much younger age of onset, FAD patients with PSEN1 mutations differed from those with NF-EAD by a history of headaches and pseudobulbar affect, as well as myoclonus and gait abnormality on examination. These may represent differences in pathophysiology between FAD and NF-EAD and in some contexts such findings should lead to genetic counseling and appropriate recommendations for genetic testing for FAD.
Literature
2.
go back to reference Mendez MF, Cummings JL (2003) Dementia: a clinical approach. Butterworth-Heinemann, Philadelphia Mendez MF, Cummings JL (2003) Dementia: a clinical approach. Butterworth-Heinemann, Philadelphia
3.
go back to reference Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A (2011) Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 76:1720–1725CrossRefPubMed Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A (2011) Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 76:1720–1725CrossRefPubMed
4.
go back to reference Galton CJ, Patterson K, Xuereb JH, Hodges JR (2000) Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123(Pt 3):484–498CrossRefPubMed Galton CJ, Patterson K, Xuereb JH, Hodges JR (2000) Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123(Pt 3):484–498CrossRefPubMed
5.
go back to reference Josephs KA, Whitwell JL, Duffy JR, Vanvoorst WA, Strand EA, Hu WT, Boeve BF, Graff-Radford NR, Parisi JE, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC (2008) Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 70:25–34CrossRefPubMed Josephs KA, Whitwell JL, Duffy JR, Vanvoorst WA, Strand EA, Hu WT, Boeve BF, Graff-Radford NR, Parisi JE, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC (2008) Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 70:25–34CrossRefPubMed
6.
go back to reference Larner AJ, Doran M (2006) Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol 253:139–158CrossRefPubMed Larner AJ, Doran M (2006) Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol 253:139–158CrossRefPubMed
7.
go back to reference Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13:597–605CrossRefPubMedPubMedCentral Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13:597–605CrossRefPubMedPubMedCentral
8.
go back to reference Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2:864–870CrossRefPubMed Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2:864–870CrossRefPubMed
9.
go back to reference Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330:1774CrossRefPubMedPubMedCentral Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330:1774CrossRefPubMedPubMedCentral
10.
go back to reference Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ (1996) The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2:1146–1150CrossRefPubMed Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ (1996) The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2:1146–1150CrossRefPubMed
11.
go back to reference Houlden H, Baker M, McGowan E, Lewis P, Hutton M, Crook R, Wood NW, Kumar-Singh S, Geddes J, Swash M, Scaravilli F, Holton JL, Lashley T, Tomita T, Hashimoto T, Verkkoniemi A, Kalimo H, Somer M, Paetau A, Martin JJ, Van Broeckhoven C, Golde T, Hardy J, Haltia M, Revesz T (2000) Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 48:806–808CrossRefPubMed Houlden H, Baker M, McGowan E, Lewis P, Hutton M, Crook R, Wood NW, Kumar-Singh S, Geddes J, Swash M, Scaravilli F, Holton JL, Lashley T, Tomita T, Hashimoto T, Verkkoniemi A, Kalimo H, Somer M, Paetau A, Martin JJ, Van Broeckhoven C, Golde T, Hardy J, Haltia M, Revesz T (2000) Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 48:806–808CrossRefPubMed
12.
go back to reference Lampe TH, Bird TD, Nochlin D, Nemens E, Risse SC, Sumi SM, Koerker R, Leaird B, Wier M, Raskind MA (1994) Phenotype of chromosome 14-linked familial Alzheimer’s disease in a large kindred. Ann Neurol 36:368–378CrossRefPubMed Lampe TH, Bird TD, Nochlin D, Nemens E, Risse SC, Sumi SM, Koerker R, Leaird B, Wier M, Raskind MA (1994) Phenotype of chromosome 14-linked familial Alzheimer’s disease in a large kindred. Ann Neurol 36:368–378CrossRefPubMed
13.
go back to reference Licht EA, McMurtray AM, Saul RE, Mendez MF (2007) Cognitive differences between early- and late-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 22:218–222CrossRefPubMed Licht EA, McMurtray AM, Saul RE, Mendez MF (2007) Cognitive differences between early- and late-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 22:218–222CrossRefPubMed
14.
go back to reference Mendez MF, Catanzaro P, Doss RC, ARguello R, Frey WH, 2nd (1994) Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol 7:230–233CrossRefPubMed Mendez MF, Catanzaro P, Doss RC, ARguello R, Frey WH, 2nd (1994) Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol 7:230–233CrossRefPubMed
15.
go back to reference Ringman JM (2005) What the study of persons at risk for familial Alzheimer’s disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol 18:228–233CrossRefPubMed Ringman JM (2005) What the study of persons at risk for familial Alzheimer’s disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol 18:228–233CrossRefPubMed
16.
go back to reference Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW (2008) Increased prevalence of significant recurrent headache in preclinical familial Alzheimer’s disease mutation carriers. Dement Geriatr Cogn Disord 25:380–384CrossRefPubMed Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW (2008) Increased prevalence of significant recurrent headache in preclinical familial Alzheimer’s disease mutation carriers. Dement Geriatr Cogn Disord 25:380–384CrossRefPubMed
17.
go back to reference Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS (1997) Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277:793–799CrossRefPubMed Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS (1997) Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277:793–799CrossRefPubMed
18.
go back to reference Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM (2006) The A431E mutation in PSEN1 causing Familial Alzheimer’s disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 7:277–279CrossRefPubMedPubMedCentral Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM (2006) The A431E mutation in PSEN1 causing Familial Alzheimer’s disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 7:277–279CrossRefPubMedPubMedCentral
19.
go back to reference Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Rondon H, Lantigua RA, Medrano M, Torres M, Arawaka S, Rogaeva E, Song YQ, Sato C, Kawarai T, Fafel KC, Boss MA, Seltzer WK, Stern Y, St George-Hyslop P, Tycko B, Mayeux R (2001) A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 286:2257–2263CrossRefPubMed Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Rondon H, Lantigua RA, Medrano M, Torres M, Arawaka S, Rogaeva E, Song YQ, Sato C, Kawarai T, Fafel KC, Boss MA, Seltzer WK, Stern Y, St George-Hyslop P, Tycko B, Mayeux R (2001) A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 286:2257–2263CrossRefPubMed
20.
go back to reference Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J (2003) Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology 60:235–239CrossRefPubMed Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J (2003) Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology 60:235–239CrossRefPubMed
21.
go back to reference Morelli L, Prat MI, Levy E, Mangone CA, Castano EM (1998) Presenilin 1 Met146Leu variant due to an A → T transversion in an early-onset familial Alzheimer’s disease pedigree from Argentina. Clin Genet 53:469–473CrossRefPubMed Morelli L, Prat MI, Levy E, Mangone CA, Castano EM (1998) Presenilin 1 Met146Leu variant due to an A → T transversion in an early-onset familial Alzheimer’s disease pedigree from Argentina. Clin Genet 53:469–473CrossRefPubMed
22.
go back to reference Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, Flores DL, Apostolova LG, Barrio JR, Small G, Silverman DH, Siu E, Cederbaum S, Hecimovic S, Malnar M, Chakraverty S, Goate AM, Bird TD, Leverenz JB (2011) Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer’s disease due to a novel PSEN1 mutation. Neurosci Lett 487:287–292CrossRefPubMed Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, Flores DL, Apostolova LG, Barrio JR, Small G, Silverman DH, Siu E, Cederbaum S, Hecimovic S, Malnar M, Chakraverty S, Goate AM, Bird TD, Leverenz JB (2011) Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer’s disease due to a novel PSEN1 mutation. Neurosci Lett 487:287–292CrossRefPubMed
23.
go back to reference Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, McNamara M, Rodes LA, DiBlasi T, Growdon WB, Seubert P, Schenk D, Growdon JH, Hyman BT, Tanzi RE (1997) A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol 41:809–813CrossRefPubMed Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, McNamara M, Rodes LA, DiBlasi T, Growdon WB, Seubert P, Schenk D, Growdon JH, Hyman BT, Tanzi RE (1997) A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol 41:809–813CrossRefPubMed
24.
go back to reference Edwards-Lee T, Wen J, Bell J, Hardy J, Chung J, Momeni P (2006) A presenilin-1 mutation (T245P) in transmembrane domain 6 causes early onset Alzheimer’s disease. Neurosci Lett 398:251–252CrossRefPubMed Edwards-Lee T, Wen J, Bell J, Hardy J, Chung J, Momeni P (2006) A presenilin-1 mutation (T245P) in transmembrane domain 6 causes early onset Alzheimer’s disease. Neurosci Lett 398:251–252CrossRefPubMed
25.
go back to reference Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–1408CrossRefPubMed Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–1408CrossRefPubMed
26.
go back to reference Borroni B, Pilotto A, Bonvicini C, Archetti S, Alberici A, Lupi A, Gennarelli M, Padovani A (2011) Atypical presentation of a novel Presenilin 1 R377 W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurol Sci Issn: 1590-1874:1-4 Borroni B, Pilotto A, Bonvicini C, Archetti S, Alberici A, Lupi A, Gennarelli M, Padovani A (2011) Atypical presentation of a novel Presenilin 1 R377 W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurol Sci Issn: 1590-1874:1-4
27.
go back to reference Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 47:867–872CrossRefPubMed Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 47:867–872CrossRefPubMed
29.
go back to reference Mendez MF, Ghajarania M, Perryman KM (2002) Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord 14:33–40CrossRefPubMed Mendez MF, Ghajarania M, Perryman KM (2002) Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord 14:33–40CrossRefPubMed
30.
go back to reference Tsai PH, Teng E, Liu C, Mendez MF (2011) Posterior cortical atrophy: evidence for discrete syndromes of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 26:413–418CrossRefPubMedPubMedCentral Tsai PH, Teng E, Liu C, Mendez MF (2011) Posterior cortical atrophy: evidence for discrete syndromes of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 26:413–418CrossRefPubMedPubMedCentral
31.
go back to reference Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer’s disease. Cortex 44:185–195CrossRefPubMed Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer’s disease. Cortex 44:185–195CrossRefPubMed
32.
go back to reference Suribhatla S, Baillon S, Dennis M, Marudkar M, Muhammad S, Munro D, Spreadbury C, Lindesay J (2004) Neuropsychological performance in early and late onset Alzheimer’s disease: comparisons in a memory clinic population. Int J Geriatr Psychiatry 19:1140–1147CrossRefPubMed Suribhatla S, Baillon S, Dennis M, Marudkar M, Muhammad S, Munro D, Spreadbury C, Lindesay J (2004) Neuropsychological performance in early and late onset Alzheimer’s disease: comparisons in a memory clinic population. Int J Geriatr Psychiatry 19:1140–1147CrossRefPubMed
33.
go back to reference Padovani A, Gilberti N, Borroni B (2011) The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer’s disease. Int J Alzheimers Dis 2011:296374PubMedPubMedCentral Padovani A, Gilberti N, Borroni B (2011) The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer’s disease. Int J Alzheimers Dis 2011:296374PubMedPubMedCentral
34.
go back to reference McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF (2008) Positron emission tomography facilitates diagnosis of early-onset Alzheimer’s disease. Eur Neurol 59:31–37CrossRefPubMed McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF (2008) Positron emission tomography facilitates diagnosis of early-onset Alzheimer’s disease. Eur Neurol 59:31–37CrossRefPubMed
35.
go back to reference Fox NC, Warrington EK, Stevens JM, Rossor MN (1996) Atrophy of the hippocampal formation in early familial Alzheimer’s disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann N Y Acad Sci 777:226–232CrossRefPubMed Fox NC, Warrington EK, Stevens JM, Rossor MN (1996) Atrophy of the hippocampal formation in early familial Alzheimer’s disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann N Y Acad Sci 777:226–232CrossRefPubMed
36.
go back to reference Pedrosa R, Teixeira-Sousa V, Fonseca S, Bastos-Leite AJ (2010) Early-onset Alzheimer disease: the contribution of neuroimaging for the diagnosis. Psychiatry Res 182:287–288CrossRefPubMed Pedrosa R, Teixeira-Sousa V, Fonseca S, Bastos-Leite AJ (2010) Early-onset Alzheimer disease: the contribution of neuroimaging for the diagnosis. Psychiatry Res 182:287–288CrossRefPubMed
37.
go back to reference Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174–6184CrossRefPubMedPubMedCentral Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174–6184CrossRefPubMedPubMedCentral
38.
go back to reference Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN (2011) Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 134:293–300CrossRefPubMed Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN (2011) Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 134:293–300CrossRefPubMed
39.
go back to reference Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H (2010) Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener 5:2CrossRefPubMedPubMedCentral Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H (2010) Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener 5:2CrossRefPubMedPubMedCentral
Metadata
Title
Comparison of clinical characteristics between familial and non-familial early onset Alzheimer’s disease
Authors
Simantini J. Karve
John M. Ringman
Albert S. Lee
Kevin O. Juarez
Mario F. Mendez
Publication date
01-10-2012
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 10/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6481-y

Other articles of this Issue 10/2012

Journal of Neurology 10/2012 Go to the issue

Pioneers in Neurology

Samuel Goldflam (1852–1932)